The Venture Codex

Participated · Series B · Oct 2025

NewLimit develops age-reprogramming medicines by using an AI-driven genomics platform to discover transcription factor combinations that reverse cellular aging and restore metabolic, vascular, and immune health. The company has discovered a prototype medicine that reverses cellular age in old human liver cells and has accelerated that program toward clinical development. NewLimit plans to transition its lead liver-cell program into investigator-led human trials targeted for late 2027 and to expand its computational biology teams to support pipeline growth. Financially, the company raised $435 million in a Series C led by Founders Fund with broad participation from venture firms and strategic investors. NewLimit was co-founded by Brian Armstrong and Blake Byers and is led by CEO and President Jacob Kimmel.

Participated · Seed · Oct 2024

Archon Biosciences emerged from stealth to commercialize engineered protein "antibody cages" (AbCs) that scaffold and multiply the effective binding of antibodies to targets. The company uses a proprietary protein design platform built on generative design and simulation tools licensed from Baker Lab at the University of Washington. Archon couples that platform with rapid in-house manufacturing and testing to accelerate biologics development and believes AbCs can turn marginal antibody interactions into robust therapeutic effects. The work underpinning AbCs is documented in a paper published in Science and the startup was spun out as the first company from Baker Lab. Archon is led by co-founder and CEO James Lazarovits and is based in Seattle. Financially, the company announced a $20 million seed financing and has additionally received about $7 million in grants from various institutes and government agencies.

Participated · Series D · Jun 2024

Sidecar Health offers major medical insurance for employers using a free‑market model that provides upfront pricing, no prior authorizations, no network restrictions, and a direct‑pay VISA benefit card for members. The company emphasizes price transparency, sharing savings with members when providers charge less than plan rates, and asserts plans are about 20% more affordable than traditional employer plans. Sidecar’s product removes restrictive formularies, coinsurance, and copays while adding financial protections against balance billing. Sidecar currently operates employer plans in Ohio and Georgia and is expanding into Florida to access a large employer market. The company has enlisted Koch Industries as a design partner for Jumbo employer coverage and will make major medical coverage available to a segment of Koch’s workforce in 2025. The business model is positioned to scale through employer adoption and regional expansion backed by recent institutional capital. Sidecar Health offers a cash-price health insurance model and a proprietary app that shows benefit amounts for more than 170,000 services and prescriptions before care. Members pay providers directly at time of care using a Sidecar Health Visa card, enabling them to access discounted self-pay rates and avoid network restraints and surprise bills. The company says members can save 40% or more compared with traditional insurance and can view what other members were charged for services. Reception has been strong: membership rose sharply in 2020, third-party Trustpilot reviews average 4.5 out of 5, and the company is operating in 16 states. Sidecar plans to expand its geographic footprint, grow its team, and invest in new insurance products, beginning with an Affordable Care Act offering for 2022 and a product for the self-funded employer market. Financially, Sidecar has raised more than $175 million since its 2018 founding and announced a Series C at a $1 billion valuation. Sidecar Health offers insurance plans that let members pay for care directly at the time of service using a Sidecar Health Visa card and mobile app, enabling access to providers’ discounted self-pay or cash rates. The company reports members save roughly 40% compared to traditional insurance and covers about 170,000 medical services and prescription drugs. Sidecar is operating in 11 states and expects to expand to several more by year’s end. The startup says it tripled membership in 2020 and plans to use new funding to grow the team and enter new geographies. Sidecar positions its product to bring price transparency and consumer choice to healthcare transactions and to push down average prices as membership scales. The company is based in Los Angeles and has raised about $40 million to date. Sidecar Health sells transparent, personalized insurance plans that give members a payment card to pay providers directly and an app to compare local provider prices. Members can see how much providers in their area charge, shop for care, and are not constrained to provider networks. The company says its policies offer robust coverage at fixed, published amounts so members know what will be paid for any health service. Sidecar touts savings of up to 40% versus traditional major medical plans. Its plans are underwritten and backed by global insurers rated A by AM Best, which the company says provides financial strength. Sidecar launched in Texas and plans to expand nationally, adding several additional states over the next 12 months.

Participated · Series B · Sep 2022

Superb AI recently attracted new capital to bolster its growth trajectory ahead of an anticipated public listing in 2026. The company closed a ₩14 billion pre-IPO round, signaling both investor interest and management’s intention to accelerate toward the public markets. Although specific product details are not disclosed in the available article excerpt, the firm’s branding and positioning indicate a technology focus that has garnered backing from institutional investors. The fresh funds provide additional runway and validate Superb AI’s valuation heading into its next phase. Management has publicly committed to pursuing an IPO in 2026, making this capital raise a bridge to the public markets. No additional information on revenue, user metrics, or previous fundraising rounds was provided in the article.

Participated · Series A · Jul 2022

Ozette develops an AI-powered computational platform for high-resolution single-cell immune discovery and annotation, automating analysis that the company says is an order of magnitude faster than manual methods. Its technology, rooted in research from the Fred Hutchinson Cancer Center and incubated at the Allen Institute for AI, has been used in published immunological discoveries including a Nature paper and a 2021 study that resolved several hundred distinct immune cell populations. Ozette has worked with partners across biopharma and with over $100M of clinical trial data to date. The company plans to expand capabilities into a multiomic platform integrating single-cell proteomics and transcriptomics and is developing a state-of-the-art immunology lab to offer additional partner services. Ozette says its machine-learning platform reduces months of analysis to days and is working to shorten that further toward minutes. The company was founded in late 2020 and operates as a Seattle-based, remote-first startup. Ozette is a Seattle-based company that has built an artificial intelligence-powered immune monitoring platform. The platform enables scientists to quickly extract reliable insights from single-cell data across instruments, experiments and disease states. It produces fully annotated data that yields interpretable, actionable results for decision-making to improve patient care and patient outcomes. Ozette is a collaboration between the Fred Hutchinson Cancer Research Center and the Allen Institute for Artificial Intelligence (AI2). The company was co-founded by Raphael Gottardo and Greg Finak and is led by CEO Dr. Ali Ansary. Ozette raised $6M in seed financing to accelerate innovation in treating disease.